An observational study in Major Depressive Disorder (MDD), Schizophrenia and Bipolar Disorder, sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University. Recruiting at 1 site in China. Open to female participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-28.
Sponsored by Second Affiliated Hospital, School of Medicine, Zhejiang University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 207 studies in Depressive Disorder, Major with a site in China — 75 open to participants now, 77 under way, 5 of them phase 3. Depressive Disorder, Major · China.
Among the 207 studies in Depressive Disorder, Major with a site in China, this one is the 14th largest by planned enrollment of the 33 observational ones that give a count, is one of 23 that started in 2025, is one of 33 observational ones, reaches primary completion later than 43 of the 76 other live ones, and was the 187th registered.
3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.
Browse Depressive Disorder, Major studies →75 of the 207 studies in Depressive Disorder, Major with a site in China are open now. Recruiting first, the newest first:
Qilu Hospital of Shandong University · Sites in China
Ages 11–19
First Affiliated Hospital of Chongqing Medical University · Sites in China
Ages 12–18
Eli Lilly and Company · Sites in China, United States, Australia and 12 more countries
Ages 18–75
First Affiliated Hospital of Chongqing Medical University · Sites in China
Ages 12–18
Guo Wenbin · Sites in China
Ages 18–45
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.
This study: 18 Years to 45 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
207 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 24 · Phase 3 20 · Phase 4 19
First in 2004; this study’s year is marked. 23 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 320 is above the median of 132 across 403 observational studies indexed under Depressive Disorder, Major.
Median enrollment 120 across the 174 interventional studies, 240 across the 33 observational. Of the 77 that completed or were terminated, 8 (10%) have results posted.
This tab as a report to print or save as PDF → With an account.
43 of 207 have an industry lead sponsor. The 10 most frequent:
Second Affiliated Hospital, School of Medicine, Zhejiang University is the lead sponsor of 1,042 studies on the registry; 499 are open to participants now.
Second Affiliated Hospital, School of Medicine, Zhejiang University has 4 studies filed under Depressive Disorder, Major — fewer than ten, so there is no comparison to draw.
21 of the studies in Depressive Disorder, Major with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04984512Phase 3Sunshine Lake Pharma Co., Ltd.The Efficacy And Safety Of Mitizodone Phosphate Tablets In The Treatment of Patient With Major Depressive Disorder | 2027-07 |
| NCT06913309Peking University Sixth HospitalClinical Efficacy, Safety, and Applicability of Home-based Bright Light Therapy in Outpatient Adolescents With Major Depressive Disorder | 2026-11-30 |
| NCT06409325Shanghai Mental Health CenterEffectiveness of MST Versus ECT for Major Depressive Episode | 2026-12-30 |
| NCT07873060Qilu Hospital of Shandong UniversityComparing 10 Hz rTMS and iTBS for Adolescent Depression | 2026-12-31 |
| NCT05480150First Affiliated Hospital of Zhejiang UniversityChinese Longitudinal and Systematic Study of Bioplar Disorder | 2026-12-31 |
Add all 21 to your calendar (.ics) → With an account.
Among the 207 studies in Depressive Disorder, Major with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is an observational study aiming to screen biomarkers associated with the diagnosis and treatment outcomes of severe mental disorders (MDD/major depressive disorder, SZ/schizophrenia, BD/bipolar disorder) through 7T ultra-high-field magnetic resonance multimodal imaging and visual perception assessment, thereby optimizing the objectivity and precision of clinical diagnosis and treatment.
I. Core Research Objectives
II. Study Subjects and Inclusion/Exclusion Criteria
Recruitment Scope
Key Criteria
III. Core Study Procedures
IV. Study Significance
Patient Group: Recruited from the Department of Psychiatry at The Second Affiliated Hospital of Zhejiang University School of Medicine, consisting of three subgroups: patients with major depressive disorder (MDD), schizophrenia (SZ), and bipolar disorder (BD), all meeting the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) diagnostic criteria.
Healthy Control (HC) Group: Recruited from the general public, with no history of mental disorder diagnosis.
All participants are aged 18 to 45 years (inclusive), meet the study's inclusion/exclusion criteria (no severe physical illnesses, no organic brain injury, etc.), and will complete non-invasive assessments (7T MRI scans, visual psychophysical experiments, cognitive tests, and clinical symptom evaluations) as required. The patient group receives standard clinical treatment (no study-induced intervention) during the study period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Recruited from Psychiatry Department of the Second Affiliated Hospital of Zhejiang University; meet DSM-5 diagnostic criteria for MDD; other inclusion/exclusion criteria consistent with Healthy Control group; receive standard clinical treatment (no study intervention), complete required assessments (pre- and post-treatment 7T MRI, behavioral tests).
Recruited from Psychiatry Department of the Second Affiliated Hospital of Zhejiang University; meet DSM-5 diagnostic criteria for MDD; other inclusion/exclusion criteria consistent with Healthy Control group; receive standard clinical treatment (no study intervention), complete required assessments (pre- and post-treatment 7T MRI, behavioral tests).
Recruited from Psychiatry Department of the Second Affiliated Hospital of Zhejiang University; meet DSM-5 diagnostic criteria for schizophrenia; other inclusion/exclusion criteria consistent with Healthy Control group; receive standard clinical treatment (no study intervention), complete required assessments.
Recruited from Psychiatry Department of the Second Affiliated Hospital of Zhejiang University; meet DSM-5 diagnostic criteria for bipolar disorder; other inclusion/exclusion criteria consistent with Healthy Control group; receive standard clinical treatment (no study intervention), complete required assessments.
Concentration of gamma-aminobutyric acid (GABA) in visual cortex
Concentration of GABA in the middle temporal visual cortex complex (MT+) and primary visual cortex (V1) measured via 7T magnetic resonance spectroscopy (MRS).Unit of Measure: Millimolar (mM)
Time frame: Baseline and 4 weeks post-treatment
Concentration of glutamate (Glu) in visual cortex
Concentration of Glu in the middle temporal visual cortex complex (MT+) and primary visual cortex (V1) measured via 7T magnetic resonance spectroscopy (MRS).Unit of Measure: Millimolar (mM)
Time frame: Baseline and 4 weeks post-treatment
Severity of depressive symptoms in MDD patients
Clinical symptom severity as measured by the Hamilton Depression Rating Scale (HAMD).Unit of Measure: Total score on HAMD scale (Range 0-52, higher scores indicate greater severity).
Time frame: Baseline and 4 weeks post-treatment
Severity of psychotic symptoms in SZ patients
Clinical symptom severity as measured by the Positive and Negative Syndrome Scale (PANSS). Unit of Measure: Total score on PANSS scale (Range 30-210, higher scores indicate greater severity).
Time frame: Baseline and 4 weeks post-treatment
Severity of manic symptoms in BD patients
Clinical symptom severity as measured by the Young Mania Rating Scale (YMRS).Unit of Measure: Total score on YMRS scale (Range 0-60, higher scores indicate greater severity).
Time frame: Baseline and 4 weeks post-treatment
Visual motion perception speed
Performance in visual motion perception assessed using standardized psychophysical experiments.Unit of Measure: Degrees per second (°/s) or threshold values
Time frame: Baseline and 4 weeks post-treatment
Binocular rivalry perceptual switching rate
Perceptual switching rate during binocular rivalry task assessed via psychophysical experiments.Unit of Measure: Number of switches per minute
Time frame: Baseline and 4 weeks post-treatment
Started Nov 2025 (actual). Primary completion is estimated for Mar 2027, 16 months after the start.
Of 121 non-industry observational studies under Depressive Disorder, Major, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 73. This study's planned 16 months is below that.
Counting every sponsor, half of 150 studies reached it within 38 months; a quarter within 21 and three quarters within 67.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Second Affiliated Hospital, School of Medicine, Zhejiang University →